SequelSEC

NIKA PHARMACEUTICALS, INC NIKA

Pharmaceutical Preparations · CIK 0001145604 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
-$156
Fiscal year ended 2024-12-31
Operating income
-$30.45K
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

NIKA PHARMACEUTICALS, INC (NIKA) reported revenue of -$156 and net income of -$30.45K for the fiscal year ended 2024-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NIKA PHARMACEUTICALS, INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NIKA PHARMACEUTICALS, INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312024-06-302023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
Revenue-$156$156$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$30.45K-$22.46K-$7.31K-$10.14K-$10.14K-$19.57K-$15.05K-$6.34K-$3.16M$6.32K
Net income-$30.45K-$22.46K-$7.31K-$10.14K-$10.14K-$19.57K-$15.05K-$6.34K-$3.16M-$6.32K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableshares 1.02BUnavailableUnavailableshares 876.09Mshares 876.09MUnavailableshares 740.60Mshares 740.60Mshares 13.20M
Pretax income-$30.45K-$22.46K-$7.31K-$10.14K-$10.14K-$19.57K-$15.05K-$6.34K-$3.16M$6.32K
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailable$0.00UnavailableUnavailable$0.00$0.00Unavailable$0.00$0.00$0.00
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$22.29K$7.50K$7.31K$10.14K$10.14K$19.57K$15.05K$6.34K$6.01K$6.32K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

NIKA PHARMACEUTICALS, INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312024-06-302023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
Cash & equivalents$2.08K$7.49K$19.60K$10.91K$11.05K$4.46K$864$3.91K$8.54K$83
Total assets$17.93K$390.32K$19.60K$10.91K$11.05K$4.46K$864$3.91K$8.54K$83
Current assets$17.93K$222.06K$19.60K$10.91K$11.05K$4.46K$864$3.91K$8.54K$83
Total liabilities$239.16K$636.93K$101.74K$85.74K$75.74K$41.34K$18.18K$6.18K$4.47KUnavailable
Current liabilities$239.16K$636.93K$101.74K$85.74K$75.74K$41.34K$18.18K$6.18K$4.47KUnavailable
Total equity incl. NCI-$221.23K-$208.78K-$82.15K-$74.84K-$64.69K-$36.89K-$17.32K-$2.27K$4.07K$83
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailable$14.10KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$196.39KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$1.50KUnavailable

Cash flow

NIKA PHARMACEUTICALS, INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312024-06-302023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
Operating cash flow-$36.67KUnavailable-$7.31K-$10.14K-$27.81K-$19.57K$15.05K$7.84K$17.14K-$6.32K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$34.00KUnavailable$16.00K$10.00K$34.40K$23.16K$12.00K$3.21K$12.97K$6.00K
Net change in cash-$2.67KUnavailable$8.69K-$143$6.59K$3.60K-$3.05K-$4.63K$8.46K-$316
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

NIKA PHARMACEUTICALS, INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312024-06-302023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.07x0.35x0.19x0.13x0.15x0.11x0.05x0.63x1.91xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NIKA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.